Eupraxia Pharmaceuticals Inc - Asset Resilience Ratio
Eupraxia Pharmaceuticals Inc (EPRX) has an Asset Resilience Ratio of 25.13% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Eupraxia Pharmaceuticals Inc PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2023)
This chart shows how Eupraxia Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See EPRX equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Eupraxia Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Eupraxia Pharmaceuticals Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0% |
| Short-term Investments | CA$8.59 Million | 25.13% |
| Total Liquid Assets | CA$8.59 Million | 25.13% |
Asset Resilience Insights
- Very High Liquidity: Eupraxia Pharmaceuticals Inc maintains exceptional liquid asset reserves at 25.13% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Eupraxia Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Eupraxia Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Novavax Inc
NASDAQ:NVAX |
Biotechnology | 53.87% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Eupraxia Pharmaceuticals Inc (2020–2023)
The table below shows the annual Asset Resilience Ratio data for Eupraxia Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | -23.06% | CA$-6.16 Million ≈ $-4.46 Million |
CA$26.72 Million ≈ $19.33 Million |
-51.78pp |
| 2022-12-31 | 28.72% | CA$7.43 Million ≈ $5.38 Million |
CA$25.88 Million ≈ $18.72 Million |
-0.13pp |
| 2021-12-31 | 28.85% | CA$9.01 Million ≈ $6.52 Million |
CA$31.22 Million ≈ $22.59 Million |
-- |
| 2020-12-31 | 0.00% | CA$0.00 ≈ $0.00 |
CA$1.45 Million ≈ $1.05 Million |
-- |
About Eupraxia Pharmaceuticals Inc
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The company's proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unm… Read more